SPYRE THERAPEUTICS INC

Spyre Therapeutics’ insider trades: Key executives buy and sell shares under Rule 10b5‑1, revealing routine corporate governance and market activity for the IBD‑focused biotech.

Spyre Therapeutics reports promising Q1 2025 financial results and announces plans to initiate Phase 2 studies for its lead candidate, SPY001, in ulcerative colitis and rheumatoid arthritis.

Spyre Therapeutics announces positive updates on its lead candidate SPY001, a novel antibody for inflammatory bowel disease, with promising pharmacokinetic and pharmacodynamic results supporting its potential as a best-in-class treatment.